Home › Research › Topics › cognitive-impairment
cognitive-impairment
847 studies tagged cognitive-impairment, dated 1982-05-01 to 2026-09-16. Bibliography: BibTeX (.bib) · RIS (.ris)
Newest in this topic
- Feasibility of remote self-administered cognitive assessment in an Alzheimer's disease treatment clinic 2026-09-16
- Structural brain imaging for newly diagnosed cognitive impairment by Medicare coverage type 2026-09-15
- Detection and Continuous Monitoring of Memory Dysfunction in Mild Cognitive Impairment and Healthy Aging Through Adaptive Computational Phenotyping 2026-09-12
Studies
847 studies carry this tag.
Date range
1982 to 2026
Top journals
- Neurology 63
- Journal of Alzheimer's disease : JAD 31
- Archives of neurology 30
- Alzheimer s & Dementia 25
- Alzheimer's & dementia : the journal of the Alzheimer's Association 21
315 journals in all.
Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.
-
Our study indicates that EEG can be used as a useful screening tool for the diagnosis and disease progression evaluation of MCI and AD.
-
Fourteen- and 16-second cut points for the CST are suitable to identify people at higher risk of functional decline among older adults in Mexico and Toledo, Spain.
-
The mean (SD) age of the study population sample (N = 3496) was 76.4 (7.6) years, and 2095 participants (60%) were female.
-
The risk of mild cognitive impairment (MCI) or dementia in individuals with subjective cognitive decline (SCD) and biomarkers indicating Alzheimer disease (AD) pathology in comparison with individuals with SCD without biomarker evidence for AD is critical to delineate the potential role of biomarker assessment in this group.
-
We previously developed a novel machine-learning-based brain age model that was sensitive to amyloid.
-
The global prevalence of MCI among community dwellers is over 15% and is affected by age, gender, education level and region of study sites.
-
Dementias are expensive diseases: the net annual cost in European healthcare is about € 28.000 per case with a strong stage dependency, of which medical care accounts for about 19%.
-
The dementia population is increasing as the world's population is growing older.
-
The proposed approach offers a fully automated identification of MCI and dementia based on a recorded neuropsychological test, providing an opportunity to develop a remote screening tool that could be adapted easily to any language.
-
Our analyses support that MNPI could improve the global cognition in older adults with MCI.
-
43/100
Cognitive dysfunctions such as mild cognitive impairment (MCI), Alzheimer's disease (AD), and other forms of dementia are recognized as common comorbidities of type 2 diabetes mellitus (T2DM).
-
On clinical data, this innovative approach for early diagnosis might provide more insight into pathophysiological processes underlying degenerative changes, as well as toward a personalized risk evaluation for pharmacological, nonpharmacological, and rehabilitation treatments.
-
Alzheimer's disease (AD) is a devastating neurodegenerative disorder with no cure, and available treatments are only able to postpone the progression of the disease.
-
Late-onset NPS improve the specificity of MCI as an at-risk state for progression to dementia.
-
Our trial showed that olfactory-stimulated oxygenation differences in the orbitofrontal cortex detected by fNIRS were associated with cognitive impairment and cognitive-related objectives.
-
47/100
Comparative effectiveness of behavioral interventions to mitigate the impacts of degeneration-based cognitive decline is not well understood.
-
Our findings suggest that VR training is an effective treatment for both people with MCI and dementia.
-
To assess whether home health agencies incur significantly higher care delivery costs for patients with cognitive impairment across three timeframes relevant to home health payment policy.
-
People with type 2 diabetes mellitus (T2DM) are at increased risk of mild cognitive impairment and dementia.
-
The relationship between mild behavioral impairment (MBI) and Alzheimer's disease (AD) is intricate and still not well investigated.
-
50/100
Cognitive decline is a broad syndrome ranging from non-pathological/age-associated cognitive decline to pathological dementia.
-
Subjective Cognitive Decline (SCD) in older adults has been identified as a risk factor for dementia, although the literature is inconsistent, and it is unclear which factors moderate progression from SCD to dementia.
-
This pilot trial aims to explore the feasibility of the trial, verify essential information of its efficacy and safety.
-
Digital cognitive tests showed good performances for MCI and dementia.
-
Although the performance of the different methods still has room for improvement, the results are promising and this methodology has a great potential as a support tool for clinicians and healthcare professionals.
-
Overall, our results highlight that the likelihood of progression from MCI to dementia is very similar to that of reversion from MCI to NC.
-
The Rey-Osterrieth Complex Figure (ROCF) test is a commonly used neuropsychological assessment tool.
-
An eight-week course of IVIG totaling 2 g/kg in MCI is safe but is not sufficient to sustain an initial reduction in brain atrophy or a temporary delay in conversion to dementia at five years.
-
The Mini-Mental State Examination (MMSE) is the best-known and the most often used short screening tool for providing an overall measure of cognitive impairment in clinical, research and community settings.
-
Our results suggest that correlating NLP and ASA with clinician observations is an objective and novel approach to measuring speech and language changes in neurodegenerative disorders.
-
65/100
Most studies have focused on dementia and suicidal behavior, with inconsistent results.
-
Anticholinergic medication burden in schizophrenia is substantial, common, conferred by multiple medication classes, and associated with cognitive impairments across all cognitive domains.
-
Conventional MCI criteria were insufficient to allow for the creation of well-defined and internationally comparable samples of MCI patients.
-
Measuring usability and UX in cognitive intervention technologies for older adults with MCI or dementia provides an integrated view that can contribute to their development according to the needs and characteristics of the target population.
-
The prevalence of MCI in China was 15.4%, which varied by demographics, lifestyles, morbidity, screening tools, and diagnostic criteria.
-
This simple and feasible cognitive impairment prediction model could identify community-dwelling elderly people at the greatest 3-year risk for cognitive impairment, which could help community nurses in the early identification of dementia.
-
Higher MCI prevalence was identified in community-dwelling older adult populations in China compared with some other countries, possibly due to more broadened criteria being adopted for confirming the diagnosis.
-
BIOFACE is a two-year study of clinical, cognition, and biomarkers that will shed light on the physiopathology and the potential utility of plasma and NPEs as non-invasive early diagnostic and prognostic biomarkers in people younger than 65 years.
-
Early diagnosis of cognitive disorders in older adults is a major healthcare priority with benefits to patients, families, and health systems.
-
60/100
MBI and SCD together were associated with the greatest risk of decline.
-
Given considerable variation in diagnostic and therapeutic practice, there is a need for national guidance on the use of neuroimaging, fluid biomarkers, cognitive testing, follow-up and diagnostic terminology in mild cognitive impairment (MCI).
-
61/100
In this diverse community-based cohort, cross-sectional data revealed significant race/ethnic disparities in the prevalence of MCI and dementia.
-
We developed models for individualized risk prediction of cognitive decline in mild cognitive impairment (MCI) using plasma biomarkers of β-amyloid (Aβ), tau and neurodegeneration.
-
Alzheimer's Disease is a complex, multifactorial, and comorbid condition.
-
The Medicare annual wellness visit-a preventive care visit free to Medicare beneficiaries enrolled in Part B-requires detection of cognitive impairment.
-
The mean (SD) age of the 4,631 participants was 67.6 (4.89) years, and 2579 (55.7%) were women.
-
Our understanding of risk factors for COVID‑19, including pre-existing medical conditions and genetic variations, is limited.
-
Participants included 10 physiatrists, 6 OTs, and 11 patients with mild cognitive impairment and mild dementia.
-
We performed a systematic review of studies focusing on the automatic prediction of the progression of mild cognitive impairment to Alzheimer's disease (AD) dementia, and a quantitative analysis of the methodological choices impacting performance.
-
Supported by very low-to-moderate certainty of evidence, physical activity/exercise has a positive effect on several cognitive and noncognitive outcomes in people with MCI and dementia, but RCTs, with low risk of bias/confounding, are still needed to confirm these relationships.
From across this tag
8 of the 846 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 8. The same 8 appear here every time.
- Exploring the neuromagnetic signatures of cognitive decline from mild cognitive impairment to Alzheimer's disease dementia
- Associations of self- and informant-reported functional impairment with cognitive performance and incident dementia
- Community screening for dementia: the Mini Mental State Exam (MMSE) and Modified Mini-Mental State Exam (3MS) compared
- Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study
- Improved dementia screening for elderly with low education in South Korea using the Cognitive Impairment Screening Test (CIST)
- Mobile technologies in the early detection of cognitive decline
- Low-Dose Lithium for Mild Cognitive Impairment: A Pilot Randomized Clinical Trial
- Neuropsychiatric symptoms in mild cognitive impairment and early Alzheimer's disease: Clinical pattern and diagnostic implications